These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 8693716)

  • 1. [Treatment of multiple myeloma--melphalan monotherapy after bone marrow transplantation].
    Hájek R; Adam Z; Krejcí M; Vásová I; Král Z; Vorlícek J
    Vnitr Lek; 1996 Apr; 42(4):278-84. PubMed ID: 8693716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation.
    Hájek R; Adam Z; Vásová I; Král Z
    Acta Med Austriaca; 1996; 23(3):85-91. PubMed ID: 8798281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Autologous transplantation of peripheral hematopoietic cells in a patient with multiple myeloma and renal insufficiency].
    Krejcí M; Doubek M; Adam Z; Hájek R; Vorlícek J; Mayer J
    Vnitr Lek; 1997 Nov; 43(11):756-8. PubMed ID: 9650509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of multiple myeloma and its complications].
    Avvisati G; Pulsoni A; Petrucci MT; Tribalto M
    Recenti Prog Med; 1990 Oct; 81(10):642-50. PubMed ID: 2291008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progress in the treatment of multiple myeloma].
    Wada M; Mizoguchi H
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1079-88. PubMed ID: 9239160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of hematopoietic stem cell autotransplantation in the treatment of multiple myeloma: initial experience at the National Bone Marrow Transplantation Center and review of the literature].
    Abdelkefi A; Ladeb S; Ben Othman T; Torjman L; Jeddi R; Ben Abdeladhim A
    Tunis Med; 2000 Oct; 78(10):548-56. PubMed ID: 11190737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy of refractory multiple myeloma. II. Therapy using high doses of alkylating cytostatic agents and radiotherapy in addition to interferon and bone marrow transplantation].
    Adam Z
    Vnitr Lek; 1993 Apr; 39(4):385-400. PubMed ID: 8351869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The treatment of multiple myeloma].
    Ludwig H; Kührer I
    Wien Klin Wochenschr; 1994; 106(14):448-54. PubMed ID: 7941591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy of multiple myeloma].
    La Verde G; Pulsoni A; Petrucci MT; Mandelli F
    Recenti Prog Med; 1997 Apr; 88(4):186-93. PubMed ID: 9206817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of multiple myeloma--present status and perspectives].
    Robak T
    Acta Haematol Pol; 1996; 27(1):5-14. PubMed ID: 8629444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [High-dose melphalan in patients with multiple myeloma].
    Moreau P; Le Bonniec M; Harousseau JL
    Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
    Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation.
    Cesaro S; Meloni G; Messina C; Pillon M; Proglia A; Lanino E; Caniggia M; Bagnulo S; Pession A; Locatelli F;
    Bone Marrow Transplant; 2001 Jul; 28(2):131-6. PubMed ID: 11509930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.
    Alvares CL; Davies FE; Horton C; Patel G; Powles R; Sirohi B; Zuha R; Gatt A; Saso R; Treleaven JG; Dearden CE; Potter MN; Ethell ME; Morgan GJ
    Br J Haematol; 2005 Jun; 129(5):607-14. PubMed ID: 15916682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
    Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
    Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
    Powles R; Raje N; Milan S; Millar B; Shepherd V; Mehta J; Singhal S; Kulkarni S; Viner C; Gore M; Cunningham D; Treleaven J
    Bone Marrow Transplant; 1997 Sep; 20(6):435-43. PubMed ID: 9313875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma.
    Reichardt VL; Okada CY; Stockerl-Goldstein KE; Bogen B; Levy R
    Biol Blood Marrow Transplant; 1997 Aug; 3(3):157-63. PubMed ID: 9310193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone.
    Desikan KR; Tricot G; Dhodapkar M; Fassas A; Siegel D; Vesole DH; Jagannath S; Singhal S; Mehta J; Spoon D; Anaissie E; Barlogie B; Munshi N
    Bone Marrow Transplant; 2000 Mar; 25(5):483-7. PubMed ID: 10713623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.